Abstract : Transcranial magnetic stimulation TMS could be a helpful addition to pharmacotherapy in treating depression ; however, more evidence of its ef cacy and safety is needed. This single-arm, open clinical study tested the ef cacy and safety of TMS in 46 patients diagnosed with major depression or bipolar disorder. TMS was performed 30 times in total, with treatment frequencies of 3-5 times weekly. Patients were examined at the 10 th and 20 th treatments, after completion of TMS treatment, and at 2 and 4 weeks after completion of treatment. Primary ef cacy endpoints were changes in Hamilton Depression Scale HAMD-17 and Patient Health Questionnaire PHQ-9 scores from baseline. Mean scores and changes in HAMD-17 and PHQ-9 were signi cantly decreased from baseline. The response rate at completion of treatment was 68.57 . Systolic blood pressure was signicantly decreased at 4 weeks after completion of treatment. Adverse events were observed in 10 patients 21.74 , including headache, discomfort, and fatigue. The present study found that patients with major depression or bipolar disorder who received TMS showed signi cant improvement in HAMD-17, PHQ-9, and Clinical Global Impression Scale scores.
Introduction
The number of people in Japan diagnosed with depression has increased rapidly in the past decade. According to reports by the Japanese Ministry of Health, Labour and Welfare, 960,000 patients had mood disorders in 2011 compared to 440,000 in 1999 1 2 . This 2-fold increase could be attributed to better methods for the diagnosis and classi cation of depression, but also to higher levels of stress in daily life. Numerous clinical studies have analyzed the pathogenesis of depression, and many drugs targeting those mechanisms have been developed 3 4 . While such drugs play a major role in treating depression, multiple dosing is required when single-agent therapy is ineffective, with side effects and the development of tolerance becoming major problems associated with the treatment 5 . The determination of a non-pharmacological means of treating depression is therefore of To whom corresponding should be addressed.
increasing importance and interest. Transcranial magnetic stimulation TMS was originally established as a test method in neurophysiology 6 , based on ndings that cerebral cortex activity could be controlled by adjusting the amount of stimulation applied. TMS was reported as an effective treatment for depression in the mid-1990s 7 ; however, a lack of consensus regarding the most effective stimulation conditions limited the adoption of TMS as an approved treatment for depression 8 . Despite this, many clinical studies have reported its efficacy with a low incidence of adverse effects 9 . In 2008 once the appropriate stimulation conditions were identi ed and established, the US Food and Drug Administration FDA approved the NeuroStar TMS Therapy System for the treatment of depression 10 .
In Japan, TMS therapy has recently been studied for the treatment of depression in combination with antidepressants ; however, evidence of its ef cacy and safety remains insuf cient. We therefore undertook an exploratory clinical study using the NeuroStar TMS Therapy System to con rm the ef cacy and safety of TMS as a new therapeutic option for the treatment of depression.
Subjects and methods

Patients
This study protocol was approved by all Institutional Review Boards of the external institutions Hattori Clinic Ethics Review Committee, Approval number : 73-1 and registered with the Japan Agency for Medical Research and Development IRB No. 11000859 . Patients who met the following inclusion criteria were enrolled in this study : 1 satis ed the diagnostic criteria of major depressive disorder or bipolar depressive episodes according to the DMS--TR Diagnostic and Statistical Manual of Mental Disorders 4 th text revision ; 2 aged between 12 and 70 years, with the consent of a legal guardian as well as that of the patient required for those 20 years of age ; 3 experienced episodes of depression within the past 3 years ; and, 4 gave written consent for participation. Our lower age limit of 12 years was based on previous reports surrounding the safety and effectiveness of TMS treatment in child and adolescent psychiatry 11 . Exclusion criteria were : 1 past history of schizophrenia, obsessive-compulsive disorder, posttraumatic stress disorder, and/or eating disorder ; 2 history of convulsive disorders such as epilepsy ; 3 history of neurological disease or idiophrenic insanity ; 4 drug or alcoholic abuse ; 5 use of magnetic devices such as a pacemaker, cochlear implant, or intracranial clip ; 6 diagnosed with serious metabolic or endocrine disease ; 7 pregnancy or possible pregnancy ; 8 strong suicidal ideation ; and 9 judged as ineligible by the physicians in charge. The eligible participants provided written informed consent following an explanation by the physicians in charge of the purpose, methods, duration, study population size, and possible bene ts and risks of the study protocols. After a nal assessment by the physicians in charge, background information on the study patients was entered into the electronic data capture EDC system in accordance with the case registration form, and then sent to the clinical data management center.
TMS treatment
TMS treatment was performed in accordance with the standard protocol described in the NeuroStar user s manual Table 1 . During TMS therapy, drugs for the treatment of depression, and for conditions other than depression, could be continued after consultation with the physicians in charge. Such drugs were used without changing the dosage and administration ; if changed or withdrawn, the details were recorded on the case reporting form.
TMS therapy was discontinued in the following cases : 1 a patient who requested discontinuation ; 2 continuation was not possible due to adverse events ; 3 depressive symptoms were aggravated ; 4 no improvement was observed and the physicians in charge judged that no bene t would be achieved with additional TMS ; 5 remission of symptoms was observed and the physicians in charge judged that further therapy was not required ; 6 a patient became pregnant ; 7 a serious protocol violation occurred ; and 8 discontinuation of treatment was judged necessary for other reasons.
Assessment of ef cacy and safety
Assessment scale scores obtained when monitoring patient background were used as baseline scores for comparison with the assessment scale scores obtained during treatment and the observation period after completion of treatment.
The primary endpoints were the amount of change in the first 17 items of the Hamilton Depression Scale HAMD-17 and in the first 9 items of the Patient Health Questionnaire PHQ-9 at completion of TMS treatment compared with baseline. Secondary endpoints were the levels of change in HAMD-17, PHQ-9, Clinical Global Impression Scale CGIS , and Young Mania Rating Scale YMRS scores at each observation time point compared with baseline ; response de ned as 50 improvement in the HAMD-17 score ; and the recurrence rate at each observation time point. Safety evaluation was based on the occurrence of adverse events, incidence of adverse events, and incidence of side effects.
Statistics
The target number of patients was 30 based on the feasibility limitations of this study. The populations for whom ef cacy and safety were evaluated consisted of all registered patients, and the analysis was conducted based on the intention-to-treat population. Primary analysis involved 
Calculation of adverse events and their incidence
For blood pressure, pulse rate, and laboratory test data, descriptive statistics of the amount of change and change over time were calculated. Measured values at baseline and each observation time point were examined using the 2-tailed paired t-test. The signi cance level was set at 5 , and multiplicity was not considered because this was an exploratory analysis. Figure 1 illustrates the study ow. After obtaining written informed consent for study participation from patients, their backgrounds were investigated and eligibility was assessed. Necessary information on eligible patients was entered into the EDC system for registering with the clinical data management center. The data were checked for eligibility. If judged as eligible, registration was completed. Registered patients received TMS treatment according to the study protocol. During treatment, patients were monitored and examined at the 10 th treatment, 20 th treatment, at the completion of treatment, and at 2 and 4 weeks thereafter to determine their condition and monitor any adverse events. This study ended after the 4-week follow-up.
Study ow
Results
Study population and patient background
Details of the patient enrolment process are shown in Table 2 . We evaluated 46 patients, comprising 32 men 68.6 and 14 women 30.4 , in the ef cacy and safety analysis. The mean age standard deviation of study participants was 34.7 12.9 years, with a mean were diagnosed with major depression and twenty-one 45.7 with bipolar disorder Table 3 . The mean duration from the start to the completion of TMS treatment was 82.2 days, and thus the mean number of treatments per week was 2.55.
Primary ef cacy outcomes
The efficacy outcomes HAMD-17, PHQ-9, CGIS, and YMRS scores at each observation time point and changes from baseline are shown in Table 4 . All ef cacy outcomes decreased signi cantly with time baseline to 4 weeks after TMS treatment ; Friedman test P 0.001, P 0.001, P 0.001, and P 0.004 for HAMD-17, PHQ-9, CGIS, and YMRS scores, respectively . Furthermore, changes from baseline measurements were significantly decreased for HAMD-17, PHQ-9, and CGIS scores P 0.001 , but not for YMRS scores. 
Secondary outcomes
The response rate and recurrence rate at each visit are shown in Table 5 . The response rate at the 10 th TMS treatment was 23.9 , and at the end of treatment it increased to 68.6 . The response rate was maintained 67.9 at 4 weeks after treatment completion. In addition, no recurrence was seen during the study period.
Safety assessment
Safety was evaluated in all patients who received TMS treatment. Patient visits with no objective ndings exceeded 90 . Furthermore, except for 94.3 at the end of treatment, the safety rate exceeded 95 for the other measurements. Although 93.5 of patients had subjective symptoms at baseline, that decreased to 82.9 at the end of treatment and to 71.4 at 4 weeks after treatment completion.
Changes in blood pressure are shown in Table 6 . Systolic blood pressure was signi cantly decreased at 4 weeks after treatment completion. Diastolic blood pressure was significantly decreased at the 10 th and 20 th treatments, and at 2 and 4 weeks after treatment completion.
There was no signi cant change in pulse rate during the study and follow-up period. Changes in laboratory blood test values are shown in Table 7 . Red and white blood cell numbers and the levels of alkaline phosphatase ALP and total protein signi cantly decreased during the study period, while levels of potassium and chlorine significantly increased. No abnormal electrocardiograms or exacerbation of manic episodes were observed.
Adverse events
No serious adverse events were recorded including seizures during or after TMS treatment, nor was there any exacerbation of manic episodes. The most commonly reported adverse effects were headache n 3, 6.5 , tiredness n 2, 4.3 , and discomfort n 4, 8.7 . Two patients 4.3 reported drowsiness. One patient 2.2 reported concentration impairment, and 1 2.2 reported a strange sensation in the scalp.
Discussion
This was the first study evaluating the efficacy and safety of TMS treatment in Japanese patients with depression. One important characteristic of this study was that TMS treatment was not conducted daily, differing from the daily regimen approved by the US FDA. Therefore, we could assess the effectiveness of TMS treatment without placing a schedule burden on patients requiring them to miss work or other obligations. Diagnostic and severity scores for depression were improved with each TMS treatment during this study, suggesting that repeated non-daily TMS treatment as well as conventional daily treatment have good therapeutic effects in patients with depression. Of note, among the many TMS treatment reports at 5 days a week, our study showed ef cacy at treatment less than 5 days a week. Based on these promising results, further study into the bene ts and scheduling of TMS treatment with a larger population is recommended.
TMS treatment yielded only a minor improvement in the YMRS score compared with the other scores examined in this study. This might be attributable to the low scores at baseline, because this study did not include patients in a manic state. On the other hand, no exacerbation of manic episodes was observed, suggesting that the improvement of depression after TMS treatment does not result in a shift to a manic state.
A decrease in blood pressure was observed after treatment in this study. Previous studies reported that TMS treatment could improve cerebral blood flow, thereby possibly leading to a reduction in blood pressure 12 13 . Accordingly, our results support the possible hypotensive effects of TMS treatment. Alternatively or additionally, the bene cial effects of TMS treatment on depression itself and/or autonomic nervous function might affect the mechanisms underlying the decrease in blood pressure observed in this study 14 . In any case, it is highly likely that the TMS treatment regimen used in this study is safe, because the blood pressure uctuation observed was within the medically acceptable range. In addition, the changes in laboratory blood tests, including the number of red and white blood cells and levels of ALP, total protein, potassium, and chlorine, were statistically signi cant but within the medically acceptable range, suggesting no /very low risk of impairment of several organs and metabolism associated with TMS treatment. Finally, no serious adverse events were observed in this study, and the commonly reported side effects were similar to those in previous studies 15 16 .
This study had several limitations. Since the treatment was open label and all patients were taking medications, the improvement of depression might be partly attributable to the additive effects of TMS treatment and medications rather than to TMS treatment alone. In addition, the follow-up period was 4 weeks and although the improvement of depression with few adverse effects was observed and maintained during the course of this study, longer-term follow-up would help to clarify the clinical signi cance of these results. Accordingly, further study with a larger patient population and longer follow-up will be necessary to corroborate our ndings on the ef cacy and safety of non-daily TMS treatment.
Conclusion
We evaluated the ef cacy and safety of treating depression using the NeuroStar Transcranial Magnetic Stimulation system in patients with depression including major depressive disorder and bipolar depressive episodes. In the 46 patients who met the inclusion criteria, HAMD-17, PHQ-9, and CGIS scores, which were the primary outcomes, showed significant decreases with TMS treatment, indicating improvement of depression. The nding that treatment 5 times weekly had equivalent effectiveness to 2 or 3 times weekly is important, since it raises the possibility of exible treatment intervals.
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